Patients with Right-Sided Primary (RSP) tumours treated with SIRT using SIR-Spheres® Y-90 resin microspheres plus mFOLFOX 6 also showed a trend towards improved PFS compared with those who received mFOLFOX6 alone (median 10.8 vs. 8.7 months, respectively; HR: 0.73 [95% CI: 0.53–1.01] p=0.053).
Graph used with kind permission from Prof Guy van Hazel
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
Van Hazel G et al. Ann Oncol 2017; ESMO 19th WCGIC, Abs. LBA-006.